3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Merkel Cell
8
Urinary Bladder Neoplasms
7
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Ovarian Neoplasms
4
Neoplasms
4
Stomach Neoplasms
3
Prostatic Neoplasms
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Sarcoma
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Squamous Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Ureteral Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Recurrence
1
Ovarian Diseases
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroendocrine Tumors
1
Interventions
Nivolumab
7
toripalimab
5
Injections
5
tislelizumab
3
pembrolizumab
3
spartalizumab
2
Paclitaxel
2
Ipilimumab
2
Gemcitabine
2
Cisplatin
2
zimberelimab
1
ulocuplumab
1
sotorasib
1
sintilimab
1
osimertinib
1
famitinib
1
donafenib
1
cemiplimab
1
binimetinib
1
avelumab
1
atezolizumab
1
WW Domain-Containing Oxidoreductase
1
Taxes
1
SHR-1701
1
Oxaliplatin
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
LY-2157299
1
Immunotherapy, Adoptive
1
Cetuximab
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Solid Tumor
×
avelumab
×
Clear all
NCT03707808
2025-01-20
myDAvIpNi
Universitair Ziekenhuis Brussel
Phase 1/2
Recruiting
18 enrolled